CureVac Cancels Initial COVID-19 Vaccine Project

The German laboratory CureVac announced on Tuesday that it was putting an end to the development of its first vaccine against COVID-19, which generated a lot of hope at first but the results were disappointing, and which was focused on another more promising immunizer.

SIGHT: Merck Pill Treatment May Be New Weapon Against COVID-19, WHO Says

This firm, specialized in messenger RNA technology, will “Focus on the development of a second generation COVID-19 vaccine”, in which it works with the British GSK, and therefore continued with the European Medicines Agency (EMA).

This also “puts an end” to the preliminary agreement with the European Union (EU), reported the laboratory.

SIGHT: Sputnik V: what you should know about its possible approval before the WHO

“The global fight against COVID-19 continues and we are determined to make a decisive contribution to it with a safe and effective vaccine,” Franz-Werner Haas, director of CureVac, guaranteed in a statement.

Clinical trials showed a much lower percentage than the drugs developed by Pfizer / BioNTech and Moderna, which use the same technology. The tests are also carried out in Peru.

SIGHT: COVID-19 | Why do WHO experts say that the Sinopharm vaccine requires three doses?

CureVac and GSK want to launch in the “next few months” a clinical study on this second-generation vaccine, which does take into account the requirements for it to be approved in 2022.

“We are pleased that CureVac is focusing on the promising second-generation vaccine.”, dubbed CV2CoV, on which the first studies show a “net improvement” over the first, said Rino Rappuoli, scientific director of GSK.

• Merck Pill Treatment May Be New Weapon Against COVID-19, WHO Says
• Merck Pill Treatment May Be New Weapon Against COVID-19, WHO Says
• COVID-19 | Why do WHO experts say that the Sinopharm vaccine requires three doses?
• Pfizer and AstraZeneca Vaccines Reduce Risk of Severe COVID-19 by 90%, Study Confirms
• AstraZeneca Experimental Drug Reduces Severe COVID-19 Cases or Death by 67%
• Molnupiravir | What You Should Know About MSD’s COVID-19 Pill
• Ivermectin: How Fake Science Invented a “Miracle” Drug Against COVID-19
• Third dose reduces the risk of severe illness from COVID-19 by 96%, according to Chilean study
• What to answer to those who still doubt whether to get vaccinated against COVID-19
• COVID-19 | Argentina starts vaccination with Sinopharm in children between 3 and 11 years old
• Everything we know about COVID-19 so far
• COVID-19 | What causes a patient in ICU to die?
• One in eight people suffered from mental disorders in Lima due to the COVID-19 pandemic
• Pfizer asks the FDA to authorize its vaccine for children between 5 and 11 years old
• Sweden suspends Moderna’s vaccine “as a precaution” for children under 30 years of age
• Johnson & Johnson requests authorization in the US for booster doses of its COVID-19 vaccine
• Sputnik V: Russia adapts quality control methods of its vaccine required by the EMA
• COVID-19 | Pfizer vaccine remains 90% effective against hospitalization for at least 6 months
• COVID-19 | Chemotherapy patients have a lower immune response to the vaccine
• European Medicines Agency approves third dose of Pfizer vaccine for people over 18 years of age
• Antivirals in the fight against COVID-19, by Elmer Huerta
• 60% of health professionals have suffered from mental disorders due to COVID-19

Follow us on twitter:

!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);

.

Deshawn